Predictors of excellent response to lithium: results from a nationwide register-based study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Predictors of excellent response to lithium : results from a nationwide register-based study. / Kessing, Lars Vedel; Hellmund, Gunnar; Andersen, Per Kragh.

In: International Clinical Psychopharmacology, Vol. 26, No. 6, 2011, p. 323-328.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Kessing, LV, Hellmund, G & Andersen, PK 2011, 'Predictors of excellent response to lithium: results from a nationwide register-based study', International Clinical Psychopharmacology, vol. 26, no. 6, pp. 323-328. https://doi.org/10.1097/YIC.0b013e32834a5cd0

APA

Kessing, L. V., Hellmund, G., & Andersen, P. K. (2011). Predictors of excellent response to lithium: results from a nationwide register-based study. International Clinical Psychopharmacology, 26(6), 323-328. https://doi.org/10.1097/YIC.0b013e32834a5cd0

Vancouver

Kessing LV, Hellmund G, Andersen PK. Predictors of excellent response to lithium: results from a nationwide register-based study. International Clinical Psychopharmacology. 2011;26(6):323-328. https://doi.org/10.1097/YIC.0b013e32834a5cd0

Author

Kessing, Lars Vedel ; Hellmund, Gunnar ; Andersen, Per Kragh. / Predictors of excellent response to lithium : results from a nationwide register-based study. In: International Clinical Psychopharmacology. 2011 ; Vol. 26, No. 6. pp. 323-328.

Bibtex

@article{caed4e3a379b4b60b413c6f738cdfc64,
title = "Predictors of excellent response to lithium: results from a nationwide register-based study",
abstract = "The aim of this study was to identify sociodemographic and clinical predictors of excellent response, that is, 'cure' of future affective episodes, to lithium in monotherapy. We used nationwide registers to identify all patients with a diagnosis of bipolar disorder in psychiatric hospital settings who were prescribed lithium from 1995 to 2006 in Denmark (N=3762). Excellent lithium responders were defined as patients who after a stabilization lithium start-up period of 6 months, continued lithium in monotherapy without getting hospitalized. The rate of excellent response to lithium in monotherapy was 8.9{\%} [95{\%} confidence interval (CI): 7.9-9.9] at 5-year follow-up and 5.4{\%} (95{\%} CI: 4.4-6.3) at 10-year follow-up. The rate of nonresponse to lithium monotherapy was significantly increased for female patients [hazards ratio (HR)=1.12, 95{\%} CI: 1.04-1.21) and for patients with a depressive index episode compared with patients in remission or with a diagnosis of other or unspecified bipolar disorder before first lithium purchase (HR=1.13, 95{\%} CI: 1.03-1.25). The rate of nonresponse increased by 3{\%} (95{\%} CI: 2-5{\%}) for every psychiatric hospitalization before first purchase of lithium. Patients with somatic comorbidity had increased rates of non-response to lithium compared with patients without somatic comorbidity (HR=1.23, 95{\%} CI: 1.00-1.52).It is concluded that the prevalence of excellent response to lithium monotherapy is low and such patients are characterized by few earlier psychiatric hospitalizations, a manic index episode before lithium and reduced somatic comorbidity.",
author = "Kessing, {Lars Vedel} and Gunnar Hellmund and Andersen, {Per Kragh}",
year = "2011",
doi = "10.1097/YIC.0b013e32834a5cd0",
language = "English",
volume = "26",
pages = "323--328",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "6",

}

RIS

TY - JOUR

T1 - Predictors of excellent response to lithium

T2 - results from a nationwide register-based study

AU - Kessing, Lars Vedel

AU - Hellmund, Gunnar

AU - Andersen, Per Kragh

PY - 2011

Y1 - 2011

N2 - The aim of this study was to identify sociodemographic and clinical predictors of excellent response, that is, 'cure' of future affective episodes, to lithium in monotherapy. We used nationwide registers to identify all patients with a diagnosis of bipolar disorder in psychiatric hospital settings who were prescribed lithium from 1995 to 2006 in Denmark (N=3762). Excellent lithium responders were defined as patients who after a stabilization lithium start-up period of 6 months, continued lithium in monotherapy without getting hospitalized. The rate of excellent response to lithium in monotherapy was 8.9% [95% confidence interval (CI): 7.9-9.9] at 5-year follow-up and 5.4% (95% CI: 4.4-6.3) at 10-year follow-up. The rate of nonresponse to lithium monotherapy was significantly increased for female patients [hazards ratio (HR)=1.12, 95% CI: 1.04-1.21) and for patients with a depressive index episode compared with patients in remission or with a diagnosis of other or unspecified bipolar disorder before first lithium purchase (HR=1.13, 95% CI: 1.03-1.25). The rate of nonresponse increased by 3% (95% CI: 2-5%) for every psychiatric hospitalization before first purchase of lithium. Patients with somatic comorbidity had increased rates of non-response to lithium compared with patients without somatic comorbidity (HR=1.23, 95% CI: 1.00-1.52).It is concluded that the prevalence of excellent response to lithium monotherapy is low and such patients are characterized by few earlier psychiatric hospitalizations, a manic index episode before lithium and reduced somatic comorbidity.

AB - The aim of this study was to identify sociodemographic and clinical predictors of excellent response, that is, 'cure' of future affective episodes, to lithium in monotherapy. We used nationwide registers to identify all patients with a diagnosis of bipolar disorder in psychiatric hospital settings who were prescribed lithium from 1995 to 2006 in Denmark (N=3762). Excellent lithium responders were defined as patients who after a stabilization lithium start-up period of 6 months, continued lithium in monotherapy without getting hospitalized. The rate of excellent response to lithium in monotherapy was 8.9% [95% confidence interval (CI): 7.9-9.9] at 5-year follow-up and 5.4% (95% CI: 4.4-6.3) at 10-year follow-up. The rate of nonresponse to lithium monotherapy was significantly increased for female patients [hazards ratio (HR)=1.12, 95% CI: 1.04-1.21) and for patients with a depressive index episode compared with patients in remission or with a diagnosis of other or unspecified bipolar disorder before first lithium purchase (HR=1.13, 95% CI: 1.03-1.25). The rate of nonresponse increased by 3% (95% CI: 2-5%) for every psychiatric hospitalization before first purchase of lithium. Patients with somatic comorbidity had increased rates of non-response to lithium compared with patients without somatic comorbidity (HR=1.23, 95% CI: 1.00-1.52).It is concluded that the prevalence of excellent response to lithium monotherapy is low and such patients are characterized by few earlier psychiatric hospitalizations, a manic index episode before lithium and reduced somatic comorbidity.

U2 - 10.1097/YIC.0b013e32834a5cd0

DO - 10.1097/YIC.0b013e32834a5cd0

M3 - Journal article

VL - 26

SP - 323

EP - 328

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 6

ER -

ID: 40169773